Pharmacology of epigenetics in brain disorders
Open accessThe DOI matches its Crossref record; 42 of the 42 references it cites were found in a registry or an index.
Abstract
Epigenetics is a rapidly growing field and holds great promise for a range of human diseases, including brain disorders such as Rett syndrome, anxiety and depressive disorders, schizophrenia, Alzheimer disease and Huntington disease. This review is concerned with the pharmacology of epigenetics to treat disorders of the epigenome whether induced developmentally or manifested/acquired later in life. In particular, we will focus on brain disorders and their treatment by drugs that modify the epigenome. While the use of DNA methyl transferase inhibitors and histone deacetylase inhibitors in in vitro and in vivo models have demonstrated improvements in disease‐related deficits, clinical trials in humans have been less promising. We will address recent advances in our understanding of the complexity of the epigenome with its many molecular players, and discuss evidence for a compromised epigenome in the context of an ageing or diseased brain. We will also draw on examples of species differences that may exist between humans and model systems, emphasizing the need for more robust pre‐clinical testing. Finally, we will discuss fundamental issues to be considered in study design when targeting the epigenome.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Epigenetic regulation of the glucocorticoid receptor in human brain associates with childhood abuse
McGowan, P. O., Sasaki, A., D'Alessio, A. C., Dymov, S., Labonté, B., Szyf, M., Turecki, G., & Meaney, M. J. (2009) · Nature Neuroscience · doi:10.1038/nn.2270 · Cited by 3,531
Plasma Homocysteine as a Risk Factor for Dementia and Alzheimer's Disease
Seshadri, S., Beiser, A., Selhub, J., Jacques, P. F., Rosenberg, I. H., D'Agostino, R. B., Wilson, P. W. F., & Wolf, P. A. (2002) · New England Journal of Medicine · doi:10.1056/nejmoa011613 · Cited by 3,237
Histone deacetylases (HDACs): characterization of the classical HDAC family
RUIJTER, A. J. M. D., GENNIP, A. H. V., CARON, H. N., KEMP, S., & KUILENBURG, A. B. P. V. (2003) · Biochemical Journal · doi:10.1042/bj20021321 · Cited by 3,114
Yang, F., Lim, G. P., Begum, A. N., Ubeda, O. J., Simmons, M. R., Ambegaokar, S. S., Chen, P. P., Kayed, R., Glabe, C. G., Frautschy, S. A., et al. (2005) · Journal of Biological Chemistry · doi:10.1074/jbc.m404751200 · Cited by 2,336
Active Genes Are Tri-Methylated at K4 of Histone H3
Santos-Rosa, H., Schneider, R., Bannister, A. J., Sherriff, J., Bernstein, B. E., Emre, N. C. T., Schreiber, S. L., Mellor, J., & Kouzarides, T. (2002) · Nature · doi:10.1038/nature01080 · Cited by 2,138 · cited 2×
“…polycomb repressor complexes have been shown to associate with trimethylated histone H3 lysine 27 (H3K27Me3) to achieve transcriptional silencing (Hansen et al., 2008), while trithorax molecules associate with histone H3K4Me3 to activate genes (Francis and Kingston, 2001; Santos-Rosa et al., 2002).”
BackgroundSchizophrenia genes, gene expression, and neuropathology: on the matter of their convergence
Harrison, P. J., & Weinberger, D. R. (2005) · Molecular Psychiatry · doi:10.1038/sj.mp.4001558 · Cited by 2,020
Systematic meta-analyses of Alzheimer disease genetic association studies: the AlzGene database
Bertram, L., McQueen, M. B., Mullin, K., Blacker, D., & Tanzi, R. E. (2007) · Nature Genetics · doi:10.1038/ng1934 · Cited by 1,857 · cited 1×
“Bertram et al. (2007) performed meta-analysis on each known polymorphism for all known AD susceptibility genes based on available genotype data from at least three independent case-control samples.”
MethodDeficiency of presenilin-1 inhibits the normal cleavage of amyloid precursor protein
De Strooper, B., Saftig, P., Craessaerts, K., Vanderstichele, H., Guhde, G., Annaert, W., Von Figura, K., & Van Leuven, F. (1998) · Nature · doi:10.1038/34910 · Cited by 1,818 · cited 1×
“The second cleavage is performed by g-secretase which is a PSEN (either PSEN1 or PSEN2)dependent enzyme (Citron et al., 1997; De Strooper et al., 1998), and produces the APP intracellular domain (AICD, also known as an APP C-terminal fragment, APP-CT) and either a 3 kDa protein (p3, when in…”
BackgroundPhiel, C. J., Zhang, F., Huang, E. Y., Guenther, M. G., Lazar, M. A., & Klein, P. S. (2001) · Journal of Biological Chemistry · doi:10.1074/jbc.m101287200 · Cited by 1,758 · cited 1×
“Long-term treatment with VPA has been shown to have neuroprotective effects on neurones which may, at least in part be due to the more recently discovered role of VPA acting as an HDAC inhibitor (Gottlicher et al., 2001; Phiel et al., 2001).”
BackgroundHistone deacetylase inhibitors: molecular mechanisms of action
Xu, W. S., Parmigiani, R. B., & Marks, P. A. (2007) · Oncogene · doi:10.1038/sj.onc.1210620 · Cited by 1,542 · cited 1×
“Mutation or inhibition of one enzyme therefore results in the relative overactivity of the other (Xu et al., 2007).”
Background
Cited by
Bromodomains as therapeutic targets
Muller, S., Filippakopoulos, P., & Knapp, S. (2011) · Expert Reviews in Molecular Medicine · doi:10.1017/s1462399411001992 · Cited by 442
Epigenetics of Stress-Related Psychiatric Disorders and Gene × Environment Interactions
Klengel, T., & Binder, E. B. (2015) · Neuron · doi:10.1016/j.neuron.2015.05.036 · Cited by 353
“The bidirectional regulation of DNA methylation and other epigenetic marks leads to the question whether unidirectional drugs such as DNMT modulators or HDAC inhibitors can actually be used for the treatment of stress-elicited psychiatric disorders (Narayan and Dragunow, 2010; Szyf, 2009).”
BackgroundAn epigenetic framework for neurodevelopmental disorders: From pathogenesis to potential therapy
Millan, M. J. (2013) · Neuropharmacology · doi:10.1016/j.neuropharm.2012.11.015 · Cited by 229
Methylation matters in child development: toward developmental behavioral epigenetics
van IJzendoorn, M. H., Bakermans-Kranenburg, M. J., & Ebstein, R. P. (2011) · Child Development Perspectives · doi:10.1111/j.1750-8606.2011.00202.x · Cited by 97
Neurogenetics and Epigenetics in Impulsive Behaviour: Impact on Reward Circuitry
Archer, T., & Blum, K. (2012) · Journal of Genetic Syndromes & Gene Therapy · doi:10.4172/2157-7412.1000115 · Cited by 54
“, DNA methyl transferase inhibitors and histone deacetylase inhibitors) for disorder-related deficits emphasises the significance of epigenome targeting [47].”
Background
Metadata
- Authors
- Narayan, P., & Dragunow, M.
- Venue
- British Journal of Pharmacology
- Publisher
- Wiley
- Published
- 2010-01
- Volume
- 159
- Issue
- 2
- Pages
- 285-303
- ISSN
- 0007-1188 (ISSN-L)
- 1476-5381
- OpenAlex
- W2103555119
- Cited by
- 67
- References
- 42
- FWCI
- 3.36
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Pharmacology of epigenetics in brain disorders. https://app.cochat.ai/papers/10.1111/j.1476-5381.2009.00526.x
- The paper
- Narayan, P., & Dragunow, M. (2010). Pharmacology of epigenetics in brain disorders. British Journal of Pharmacology. https://doi.org/10.1111/j.1476-5381.2009.00526.x
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.